Fri, Feb 28, 9:56 PM (57 days ago)
**Edwards Lifesciences Corporation (EW) 2024 10-K Summary** **Financial Performance:** In 2024, Edwards Lifesciences reported net sales of $5,439.5 million, up 8.6% from 2023, primarily driven by growth in Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT). Net income surged to $4,174.6 million, including a one-time gain of $3.3 billion from the sale of the Critical Care product group. Earnings per share (EPS) increased to $6.97, reflecting strong operational performance. **Strategic Overview:** The divestiture of the Critical Care segment for $4.2 billion enables a sharper focus on enhancing TAVR and TMTT offerings and investing in interventional heart failure technologies. The company has also made significant acquisitions, including Endotronix and Innovalve Bio Medical, expanding its product portfolio. **Future Outlook:** Edwards aims to leverage its leading market position in structural heart innovations, with ongoing investments in R&D (19% of sales) to drive future growth. **Risk Factors:** Key risks include competition, regulatory challenges, reliance on third-party suppliers, and potential impacts from public health crises. The company also faces uncertainties related to tax positions and ongoing litigation. **Financial Condition:** As of December 31, 2024, total assets stood at $13,055.3 million, with cash and equivalents of $3,045.2 million, reflecting robust liquidity. Operating expenses increased due to strategic growth initiatives and acquisitions.